Shares of Be­yond­Spring sky­rock­et on new, pos­i­tive can­cer drug tri­al re­sults

Some­times re­sults come along that shock even a biotech’s be­liev­ers.

On Wednes­day, Be­yond­Spring, a small New York biotech with an off­beat ap­proach to im­munother­a­py, an­nounced its lead drug sig­nif­i­cant­ly ex­tend­ed non-small cell lung can­cer pa­tients’ lives in a large tri­al. Al­though the com­pa­ny did not re­lease the ex­act sur­vival da­ta, it said that near­ly twice as many pa­tients were alive af­ter two years on the drug arm than on the stan­dard-of-care arm.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER